Literature DB >> 27372757

LSD1 Histone Demethylase Assays and Inhibition.

D Hayward1, P A Cole2.   

Abstract

The lysine-specific demethylase (LSD1) is a flavin-dependent amine oxidase that selectively removes one or two methyl groups from histone H3 at the Lys4 position. Along with histone deacetylases 1 and 2, LSD1 is involved in epigenetically silencing gene expression. LSD1 has been implicated as a potential therapeutic target in cancer and other diseases. In this chapter, we discuss several approaches to measure LSD1 demethylase activity and their relative strengths and limitations for inhibitor discovery and mechanistic characterization. In addition, we review the principal established chemical functional groups derived from monoamine oxidase inhibitors that have been investigated in the context of LSD1 as demethylase inhibitors. Finally, we highlight a few examples of recently developed LSD1 mechanism-based inactivators and their biomedical applications.
© 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Amine oxidase; Cyclopropylamine; Histone; Hydrazine; Inhibitor; Kinetics; Mass spectrometry

Mesh:

Substances:

Year:  2016        PMID: 27372757      PMCID: PMC5178825          DOI: 10.1016/bs.mie.2016.01.020

Source DB:  PubMed          Journal:  Methods Enzymol        ISSN: 0076-6879            Impact factor:   1.600


  56 in total

Review 1.  Medicinal chemistry insights in the discovery of novel LSD1 inhibitors.

Authors:  Xueshun Wang; Boshi Huang; Takayoshi Suzuki; Xinyong Liu; Peng Zhan
Journal:  Epigenomics       Date:  2015-12-08       Impact factor: 4.778

2.  Structure-activity study for (bis)ureidopropyl- and (bis)thioureidopropyldiamine LSD1 inhibitors with 3-5-3 and 3-6-3 carbon backbone architectures.

Authors:  Shannon L Nowotarski; Boobalan Pachaiyappan; Steven L Holshouser; Craig J Kutz; Youxuan Li; Yi Huang; Shiv K Sharma; Robert A Casero; Patrick M Woster
Journal:  Bioorg Med Chem       Date:  2015-02-07       Impact factor: 3.641

3.  A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC.

Authors:  Helai P Mohammad; Kimberly N Smitheman; Chandrashekhar D Kamat; David Soong; Kelly E Federowicz; Glenn S Van Aller; Jess L Schneck; Jeffrey D Carson; Yan Liu; Michael Butticello; William G Bonnette; Shelby A Gorman; Yan Degenhardt; Yuchen Bai; Michael T McCabe; Melissa B Pappalardi; Jiri Kasparec; Xinrong Tian; Kenneth C McNulty; Meagan Rouse; Patrick McDevitt; Thau Ho; Michelle Crouthamel; Timothy K Hart; Nestor O Concha; Charles F McHugh; William H Miller; Dashyant Dhanak; Peter J Tummino; Christopher L Carpenter; Neil W Johnson; Christine L Hann; Ryan G Kruger
Journal:  Cancer Cell       Date:  2015-07-13       Impact factor: 31.743

4.  A specific LSD1/KDM1A isoform regulates neuronal differentiation through H3K9 demethylation.

Authors:  Benoit Laurent; Lv Ruitu; Jernej Murn; Kristina Hempel; Ryan Ferrao; Yang Xiang; Shichong Liu; Benjamin A Garcia; Hao Wu; Feizhen Wu; Hanno Steen; Yang Shi
Journal:  Mol Cell       Date:  2015-02-12       Impact factor: 17.970

5.  Brain-penetrant LSD1 inhibitors can block memory consolidation.

Authors:  Ramesh Neelamegam; Emily L Ricq; Melissa Malvaez; Debasis Patnaik; Stephanie Norton; Stephen M Carlin; Ian T Hill; Marcelo A Wood; Stephen J Haggarty; Jacob M Hooker
Journal:  ACS Chem Neurosci       Date:  2011-10-18       Impact factor: 4.418

6.  Alternative splicing of the histone demethylase LSD1/KDM1 contributes to the modulation of neurite morphogenesis in the mammalian nervous system.

Authors:  Cristina Zibetti; Antonio Adamo; Claudia Binda; Federico Forneris; Emanuela Toffolo; Chiara Verpelli; Enrico Ginelli; Andrea Mattevi; Carlo Sala; Elena Battaglioli
Journal:  J Neurosci       Date:  2010-02-17       Impact factor: 6.167

7.  A scintillation proximity assay for histone demethylases.

Authors:  Wenyu Yu; Mohammad S Eram; Taraneh Hajian; Aleksandra Szykowska; Nicola Burgess-Brown; Masoud Vedadi; Peter J Brown
Journal:  Anal Biochem       Date:  2014-07-08       Impact factor: 3.365

8.  Mechanistic analysis of a suicide inactivator of histone demethylase LSD1.

Authors:  Lawrence M Szewczuk; Jeffrey C Culhane; Maojun Yang; Ananya Majumdar; Hongtao Yu; Philip A Cole
Journal:  Biochemistry       Date:  2007-05-19       Impact factor: 3.162

9.  Measurement of lysine-specific demethylase-1 activity in the nuclear extracts by flow-injection based time-of-flight mass spectrometry.

Authors:  Chiharu Sakane; Hiromichi Ohta; Yoshihiro Shidoji
Journal:  J Clin Biochem Nutr       Date:  2015-02-13       Impact factor: 3.114

10.  LSD1n is an H4K20 demethylase regulating memory formation via transcriptional elongation control.

Authors:  Jianxun Wang; Francesca Telese; Yuliang Tan; Wenbo Li; Chunyu Jin; Xin He; Harihar Basnet; Qi Ma; Daria Merkurjev; Xiaoyan Zhu; Zhijie Liu; Jie Zhang; Kenny Ohgi; Havilah Taylor; Ryan R White; Cagdas Tazearslan; Yousin Suh; Todd S Macfarlan; Samuel L Pfaff; Michael G Rosenfeld
Journal:  Nat Neurosci       Date:  2015-07-27       Impact factor: 24.884

View more
  12 in total

1.  Activity-dependent Regulation of Histone Lysine Demethylase KDM1A by a Putative Thiol/Disulfide Switch.

Authors:  Emily L Ricq; Jacob M Hooker; Stephen J Haggarty
Journal:  J Biol Chem       Date:  2016-09-15       Impact factor: 5.157

Review 2.  Inhibitors of Protein Methyltransferases and Demethylases.

Authors:  H Ümit Kaniskan; Michael L Martini; Jian Jin
Journal:  Chem Rev       Date:  2017-03-24       Impact factor: 60.622

Review 3.  Toward development of epigenetic drugs for central nervous system disorders: Modulating neuroplasticity via H3K4 methylation.

Authors:  Emily L Ricq; Jacob M Hooker; Stephen J Haggarty
Journal:  Psychiatry Clin Neurosci       Date:  2016-09-07       Impact factor: 5.188

4.  Notch Represses Transcription by PRC2 Recruitment to the Ternary Complex.

Authors:  Xiaoqing Han; Prathibha Ranganathan; Christos Tzimas; Kelly L Weaver; Ke Jin; Luisana Astudillo; Wen Zhou; Xiaoxia Zhu; Bin Li; David J Robbins; Anthony J Capobianco
Journal:  Mol Cancer Res       Date:  2017-06-05       Impact factor: 5.852

5.  Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors.

Authors:  Jay H Kalin; Muzhou Wu; Andrea V Gomez; Yun Song; Jayanta Das; Dawn Hayward; Nkosi Adejola; Mingxuan Wu; Izabela Panova; Hye Jin Chung; Edward Kim; Holly J Roberts; Justin M Roberts; Polina Prusevich; Jeliazko R Jeliazkov; Shourya S Roy Burman; Louise Fairall; Charles Milano; Abdulkerim Eroglu; Charlotte M Proby; Albena T Dinkova-Kostova; Wayne W Hancock; Jeffrey J Gray; James E Bradner; Sergio Valente; Antonello Mai; Nicole M Anders; Michelle A Rudek; Yong Hu; Byungwoo Ryu; John W R Schwabe; Andrea Mattevi; Rhoda M Alani; Philip A Cole
Journal:  Nat Commun       Date:  2018-01-04       Impact factor: 14.919

Review 6.  Epigenetic Mechanisms of Tamoxifen Resistance in Luminal Breast Cancer.

Authors:  Hany A Abdel-Hafiz
Journal:  Diseases       Date:  2017-07-06

Review 7.  Epigenetics in ovarian cancer: premise, properties, and perspectives.

Authors:  Qilian Yang; Yuqing Yang; Nianxin Zhou; Kexin Tang; Wayne Bond Lau; Bonnie Lau; Wei Wang; Lian Xu; Zhengnan Yang; Shuang Huang; Xin Wang; Tao Yi; Xia Zhao; Yuquan Wei; Hongjing Wang; Linjie Zhao; Shengtao Zhou
Journal:  Mol Cancer       Date:  2018-07-31       Impact factor: 27.401

Review 8.  [Progress on epigenetic regulation of iron homeostasis].

Authors:  Lingyan Duan; Xiangju Yin; Hong'en Meng; Xuexian Fang; Junxia Min; Fudi Wang
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2020-05-25

9.  Lysine-14 acetylation of histone H3 in chromatin confers resistance to the deacetylase and demethylase activities of an epigenetic silencing complex.

Authors:  Mingxuan Wu; Dawn Hayward; Jay H Kalin; Yun Song; John Wr Schwabe; Philip A Cole
Journal:  Elife       Date:  2018-06-05       Impact factor: 8.140

10.  3-Chloro-N'-(2-hydroxybenzylidene) benzohydrazide: An LSD1-Selective Inhibitor and Iron-Chelating Agent for Anticancer Therapy.

Authors:  Federica Sarno; Chiara Papulino; Gianluigi Franci; Jeanette H Andersen; Bastien Cautain; Colombina Melardo; Lucia Altucci; Angela Nebbioso
Journal:  Front Pharmacol       Date:  2018-09-07       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.